{"identifier":"/us/usc/t42/s287d","title_num":"42","num":"§ 287d.","heading":"Office of Research on Women’s Health","status":null,"guid":"id5609a448-d74c-11ea-9a0b-9c360331c9b3","source_credit":"(July 1, 1944, ch. 373, title IV, § 486, as added Pub. L. 103–43, title I, § 141(a)(3), June 10, 1993, 107 Stat. 136; amended Pub. L. 105–340, title I, § 106, Oct. 31, 1998, 112 Stat. 3193; Pub. L. 111–148, title III, § 3509(c), Mar. 23, 2010, 124 Stat. 534; Pub. L. 114–255, div. A, title II, § 2038(c), Dec. 13, 2016, 130 Stat. 1065.)","seq_in_title":627,"parent_identifier":"/us/usc/t42/ch6A/schIII/ptF","ancestors":[{"identifier":"/us/usc/t42","level":"title","num":"Title 42—","heading":"THE PUBLIC HEALTH AND WELFARE","status":null,"is_section":false},{"identifier":"/us/usc/t42/ch6A","level":"chapter","num":"CHAPTER 6A—","heading":"PUBLIC HEALTH SERVICE","status":null,"is_section":false},{"identifier":"/us/usc/t42/ch6A/schIII","level":"subchapter","num":"SUBCHAPTER III—","heading":"NATIONAL RESEARCH INSTITUTES","status":null,"is_section":false},{"identifier":"/us/usc/t42/ch6A/schIII/ptF","level":"part","num":"Part F—","heading":"Research on Women’s Health","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"id887542af-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d\"><num value=\"287d\">§ 287d.</num><heading> Office of Research on Women’s Health</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id887542b0-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> Establishment</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">There is established within the Office of the Director of NIH an office to be known as the Office of Research on Women’s Health (in this part referred to as the “Office”). The Office shall be headed by a director, who shall be appointed by the Director of NIH and who shall report directly to the Director.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id887542b1-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Purpose</heading><chapeau>The Director of the Office shall—</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b2-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/1\"><num value=\"1\">(1)</num><content> identify projects of research on women’s health that should be conducted or supported by the national research institutes;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b3-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/2\"><num value=\"2\">(2)</num><content> identify multidisciplinary research relating to research on women’s health that should be so conducted or supported;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b4-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/3\"><num value=\"3\">(3)</num><content> carry out paragraphs (1) and (2) with respect to the aging process in women, with priority given to menopause;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b5-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/4\"><num value=\"4\">(4)</num><content> promote coordination and collaboration among entities conducting research identified under any of paragraphs (1) through (3);</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b6-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/5\"><num value=\"5\">(5)</num><content> encourage the conduct of such research by entities receiving funds from the national research institutes;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b7-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/6\"><num value=\"6\">(6)</num><content> recommend an agenda for conducting and supporting such research;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b8-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/7\"><num value=\"7\">(7)</num><content> promote the sufficient allocation of the resources of the national research institutes for conducting and supporting such research;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542b9-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/8\"><num value=\"8\">(8)</num><content> assist in the administration of <ref href=\"/us/usc/t42/s289a–2\">section 289a–2 of this title</ref> with respect to the inclusion of women as subjects in clinical research; and</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542ba-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/b/9\"><num value=\"9\">(9)</num><content> prepare the report required in <ref href=\"/us/usc/t42/s287d–2\">section 287d–2 of this title</ref>.</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id887542bb-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> Coordinating Committee</heading><paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887542bc-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/1\"><num value=\"1\">(1)</num><content> In carrying out subsection (b), the Director of the Office shall establish a committee to be known as the Coordinating Committee on Research on Women’s Health (in this subsection referred to as the “Coordinating Committee”).</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887542bd-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/2\"><num value=\"2\">(2)</num><content> The Coordinating Committee shall be composed of the Directors of the national research institutes (or the senior-level staff designees of the Directors).</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887542be-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/3\"><num value=\"3\">(3)</num><content> The Director of the Office shall serve as the chair of the Coordinating Committee.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887542bf-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4\"><num value=\"4\">(4)</num><chapeau> With respect to research on women’s health, the Coordinating Committee shall assist the Director of the Office in—</chapeau><subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542c0-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4/A\"><num value=\"A\">(A)</num><content> identifying the need for such research, and making an estimate each fiscal year of the funds needed to adequately support the research;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887542c1-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4/B\"><num value=\"B\">(B)</num><content> identifying needs regarding the coordination of research activities, including intramural and extramural multidisciplinary activities;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569d2-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4/C\"><num value=\"C\">(C)</num><content> supporting the development of methodologies to determine the circumstances in which obtaining data specific to women (including data relating to the age of women and the membership of women in ethnic or racial groups) is an appropriate function of clinical trials of treatments and therapies;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569d3-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4/D\"><num value=\"D\">(D)</num><content> supporting the development and expansion of clinical trials of treatments and therapies for which obtaining such data has been determined to be an appropriate function; and</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569d4-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/c/4/E\"><num value=\"E\">(E)</num><content> encouraging the national research institutes to conduct and support such research, including such clinical trials.</content>\n</subparagraph>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id887569d5-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d\"><num value=\"d\" class=\"bold\">(d)</num><heading class=\"bold\"> Advisory Committee</heading><paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569d6-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/1\"><num value=\"1\">(1)</num><content> In carrying out subsection (b), the Director of the Office shall establish an advisory committee to be known as the Advisory Committee on Research on Women’s Health (in this subsection referred to as the “Advisory Committee”).</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569d7-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/2\"><num value=\"2\">(2)</num><content> The Advisory Committee shall be composed of no fewer than 12, and not more than 18 individuals, who are not officers or employees of the Federal Government. The Director of NIH shall make appointments to the Advisory Committee from among physicians, practitioners, scientists, and other health professionals, whose clinical practice, research specialization, or professional expertise includes a significant focus on research on women’s health. A majority of the members of the Advisory Committee shall be women.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569d8-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/3\"><num value=\"3\">(3)</num><content> The Director of the Office shall serve as the chair of the Advisory Committee.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569d9-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4\"><num value=\"4\">(4)</num><chapeau> The Advisory Committee shall—</chapeau><subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569da-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A\"><num value=\"A\">(A)</num><chapeau> advise the Director of the Office on appropriate research activities to be undertaken by the national research institutes with respect to—</chapeau><clause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id887569db-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A/i\"><num value=\"i\">(i)</num><content> research on women’s health;</content>\n</clause>\n<clause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id887569dc-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A/ii\"><num value=\"ii\">(ii)</num><content> research on gender differences in clinical drug trials, including responses to pharmacological drugs;</content>\n</clause>\n<clause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id887569dd-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A/iii\"><num value=\"iii\">(iii)</num><content> research on gender differences in disease etiology, course, and treatment;</content>\n</clause>\n<clause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id887569de-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A/iv\"><num value=\"iv\">(iv)</num><content> research on obstetrical and gynecological health conditions, diseases, and treatments; and</content>\n</clause>\n<clause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id887569df-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/A/v\"><num value=\"v\">(v)</num><content> research on women’s health conditions which require a multidisciplinary approach;</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e0-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/B\"><num value=\"B\">(B)</num><content> report to the Director of the Office on such research;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e1-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/C\"><num value=\"C\">(C)</num><content> provide recommendations to such Director regarding activities of the Office (including recommendations on the development of the methodologies described in subsection (c)(4)(C) and recommendations on priorities in carrying out research described in subparagraph (A)); and</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e2-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/4/D\"><num value=\"D\">(D)</num><content> assist in monitoring compliance with <ref href=\"/us/usc/t42/s289a–2\">section 289a–2 of this title</ref> regarding the inclusion of women in clinical research.</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569e3-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5\"><num value=\"5\">(5)</num><subparagraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569e4-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5/A\"><num value=\"A\">(A)</num><chapeau> The Advisory Committee shall prepare a biennial report describing the activities of the Committee, including findings made by the Committee regarding—</chapeau><clause style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e5-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5/A/i\"><num value=\"i\">(i)</num><content> compliance with <ref href=\"/us/usc/t42/s289a–2\">section 289a–2 of this title</ref>;</content>\n</clause>\n<clause style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e6-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5/A/ii\"><num value=\"ii\">(ii)</num><content> the extent of expenditures made for research on women’s health by the agencies of the National Institutes of Health; and</content>\n</clause>\n<clause style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id887569e7-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5/A/iii\"><num value=\"iii\">(iii)</num><content> the level of funding needed for such research.</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"id887569e8-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/d/5/B\"><num value=\"B\">(B)</num><content> The report required in subparagraph (A) shall be submitted to the Director of NIH for inclusion in the report required in <ref href=\"/us/usc/t42/s283\">section 283 of this title</ref>.</content>\n</subparagraph>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id887569e9-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/e\"><num value=\"e\" class=\"bold\">(e)</num><heading class=\"bold\"> Representation of women among researchers</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The Secretary, acting through the Assistant Secretary for Personnel and in collaboration with the Director of the Office, shall determine the extent to which women are represented among senior physicians and scientists of the national research institutes and among physicians and scientists conducting research with funds provided by such institutes, and as appropriate, carry out activities to increase the extent of such representation.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id88758ffa-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f\"><num value=\"f\" class=\"bold\">(f)</num><heading class=\"bold\"> Definitions</heading><chapeau>For purposes of this part:</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id88758ffb-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f/1\"><num value=\"1\">(1)</num><chapeau> The term “women’s health conditions”, with respect to women of all age, ethnic, and racial groups, means all diseases, disorders, and conditions (including with respect to mental health)—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id88758ffc-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f/1/A\"><num value=\"A\">(A)</num><content> unique to, more serious, or more prevalent in women;</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id88758ffd-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f/1/B\"><num value=\"B\">(B)</num><content> for which the factors of medical risk or types of medical intervention are different for women, or for which it is unknown whether such factors or types are different for women; or</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"id88758ffe-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f/1/C\"><num value=\"C\">(C)</num><content> with respect to which there has been insufficient clinical research involving women as subjects or insufficient clinical data on women.</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id88758fff-86fb-11e9-b915-8b3e54686b9f\" identifier=\"/us/usc/t42/s287d/f/2\"><num value=\"2\">(2)</num><content> The term “research on women’s health” means research on women’s health conditions, including research on preventing such conditions.</content>\n</paragraph>\n</subsection>\n<sourceCredit id=\"id88759000-86fb-11e9-b915-8b3e54686b9f\">(<ref href=\"/us/act/1944-07-01/ch373\">July 1, 1944, ch. 373</ref>, title IV, § 486, as added <ref href=\"/us/pl/103/43/tI/s141/a/3\">Pub. L. 103–43, title I, § 141(a)(3)</ref>, <date date=\"1993-06-10\">June 10, 1993</date>, <ref href=\"/us/stat/107/136\">107 Stat. 136</ref>; amended <ref href=\"/us/pl/105/340/tI/s106\">Pub. L. 105–340, title I, § 106</ref>, <date date=\"1998-10-31\">Oct. 31, 1998</date>, <ref href=\"/us/stat/112/3193\">112 Stat. 3193</ref>; <ref href=\"/us/pl/111/148/tIII/s3509/c\">Pub. L. 111–148, title III, § 3509(c)</ref>, <date date=\"2010-03-23\">Mar. 23, 2010</date>, <ref href=\"/us/stat/124/534\">124 Stat. 534</ref>; <ref href=\"/us/pl/114/255/dA/tII/s2038/c\">Pub. L. 114–255, div. A, title II, § 2038(c)</ref>, <date date=\"2016-12-13\">Dec. 13, 2016</date>, <ref href=\"/us/stat/130/1065\">130 Stat. 1065</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"id88759001-86fb-11e9-b915-8b3e54686b9f\">\n<note style=\"-uslm-lc:I74\" topic=\"amendments\" id=\"id88759002-86fb-11e9-b915-8b3e54686b9f\"><heading class=\"centered smallCaps\">Amendments</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">2016—Subsec. (c)(2). <ref href=\"/us/pl/114/255\">Pub. L. 114–255</ref> substituted “senior-level staff designees” for “designees”.</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">2010—Subsec. (a). <ref href=\"/us/pl/111/148\">Pub. L. 111–148</ref> inserted “and who shall report directly to the Director” before period at end.</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">1998—Subsec. (d)(2). <ref href=\"/us/pl/105/340\">Pub. L. 105–340</ref> substituted “NIH” for “the Office”.</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"miscellaneous\" id=\"id88759003-86fb-11e9-b915-8b3e54686b9f\"><heading class=\"centered smallCaps\">Termination of Advisory Committees</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Advisory committees established after <date date=\"1973-01-05\">Jan. 5, 1973</date>, to terminate not later than the expiration of the 2-year period beginning on the date of their establishment, unless, in the case of a committee established by the President or an officer of the Federal Government, such committee is renewed by appropriate action prior to the expiration of such 2-year period, or in the case of a committee established by Congress, its duration is otherwise provided for by law. See <ref href=\"/us/pl/92/463/s14\">section 14 of Pub. L. 92–463</ref>, <date date=\"1972-10-06\">Oct. 6, 1972</date>, <ref href=\"/us/stat/86/776\">86 Stat. 776</ref>, set out in the Appendix to Title 5, Government Organization and Employees.</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\"><ref href=\"/us/pl/93/641/s6\">Pub. L. 93–641, § 6</ref>, <date date=\"1975-01-04\">Jan. 4, 1975</date>, <ref href=\"/us/stat/88/2275\">88 Stat. 2275</ref>, set out as a note under <ref href=\"/us/usc/t42/s217a\">section 217a of this title</ref>, provided that an advisory committee established pursuant to the Public Health Service Act shall terminate at such time as may be specifically prescribed by an Act of Congress enacted after <date date=\"1975-01-04\">Jan. 4, 1975</date>.</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"116-151","currency_date":"2020-08-03","congress":116,"law_num":151,"excluded_laws":[],"update_num":null,"seq":210,"is_partial":false,"caveat":null,"titles_affected":["06","42"],"ingested_titles":[]},"served_from":{"label":"116-151","currency_date":"2020-08-03","congress":116,"law_num":151,"excluded_laws":[],"update_num":null,"seq":210,"is_partial":false,"caveat":null,"titles_affected":["06","42"],"ingested_titles":[]},"content_first_seen":{"label":"116-19","currency_date":"2019-05-31","congress":116,"law_num":19,"excluded_laws":[],"update_num":null,"seq":174,"is_partial":false,"caveat":null,"titles_affected":["25","42"],"ingested_titles":[]},"is_exact":true,"note":null}